Navigation Links
Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
Date:12/10/2012

RIDGEFIELD, Conn., Dec. 10, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.  In this study, higher rates of objective response (primary endpoint) and a trend for longer median event free survival (EFS) (a secondary endpoint) were observed in patients treated with volasertib in combination with low-dose cytarabine (LDAC) compared to patients treated with LDAC alone. Presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, Ga., these results support the initiation of a Phase III study of volasertib in combination with LDAC expected to start in early 2013. 

AML is one of the most common types of leukemia in adults.2  A common treatment approach is intensive chemotherapy to induce disease remission, followed by consolidation/maintenance chemotherapy.3,4  However, many patients over 65 years of age – whose prognosis is typically poor5 – are ineligible for this approach, which involves large doses of chemotherapy over short periods of time.3,4 

The open-label study enrolled 87 adult patients randomly assigned to receive either volasertib in combination with LDAC (n=42) or LDAC alone (n=45).   The primary endpoint was objective response (complete remission [CR] or CR with incomplete blood count recovery [CRi]).  Objective responses were observed in 31 percent of patients (13 of 42 patients) treated with the combination of volasertib plus LDAC compared with 13.3 percent of the patients (6 of 45 patients) treated with LDAC alone (odds ratio: 2.91; p = 0.0523).  The median (range) time to remission was 71 (2
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Announces Equine Research Awards
2. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
3. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
4. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
10. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
11. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... FRANCISCO, Calif. , Aug. 3, 2015 /PRNewswire/ ... the treatment of cancer, today announced the promotion ... Debanjan Ray , who previously served ... management, has been promoted to senior vice president ... CytomX, Mr. Ray held positions as the vice ...
(Date:8/3/2015)... OSAKA, Japan and FLORHAM PARK, ... today announced that once-daily naldemedine met its primary and ... for the treatment of opioid-induced constipation (OIC) in adult ... oral, peripherally acting mu-opioid receptor antagonist (PAMORA). This is ... its primary and key secondary endpoints. Study ...
(Date:8/3/2015)... Inc. (PK:ECIA), a medical device company owning patented surgical ... invasive surgery, today announced financial results for its fiscal ... The Company posted quarterly net revenue of $2.454 ... or $(0.02) per share. These results compare to net ... $202 thousand, or $(0.02) per share, in the year-ago ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... , ST. LOUIS , Feb. 8 ... its first Stereotaxis Magnetic Navigation System in Taiwan at ... a Grand Opening event on January 26 that received ... been successfully performed using Stereotaxis at the hospital. , "All too ...
... Md. , Feb. 8 Novavax, Inc. (Nasdaq: ... to discontinue negotiations in its pursuit of the previously announced ... Novavax,s virus-like-particle (VLP)-based vaccines against influenza in the country of ... inability to agree on acceptable terms of the proposed collaboration ...
Cached Medicine Technology:Stereotaxis Installs First System in Taiwan 2Stereotaxis Installs First System in Taiwan 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 2Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 4
(Date:8/3/2015)... ... August 03, 2015 , ... ... ® and Navigant Center for Healthcare Research and Policy Analysis show widespread support ... of respondents said they agreed or strongly agreed that the controversial law passed ...
(Date:8/3/2015)... ... ... A July 9 article from USA Today has revealed a ... American Dental Association. According to a study by the American Dental Association, from 2000 ... single year to 2.2 million a year. Dentists and ADA officials all point to ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... global insurance brokerage firm, announced today that Joe Williams has joined its growing ... sales, and delivering HUB's differentiated service model to his clients. Mr. Williams will ...
(Date:8/3/2015)... ... ... The American Institute of Architects (AIA) and ... a wide range of initiatives ranging from code development and compliance to sustainability ... membership, consisting of practicing design professionals, code officials, and the building industry representatives, ...
(Date:8/2/2015)... ... August 03, 2015 , ... For many “would be” entrepreneurs, starting a new business can ... can’t afford to start a business.” Neither needs be a major obstacle. , The ... to start a business and be successful. The risks of starting a business can be ...
Breaking Medicine News(10 mins):Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5
... how much control a person has over their own health ... that when doctor and patient attitudes on the issue match ... Published online and in the May issue of the ... part of a growing body of evidence indicating that patient-physician ...
... have already adopted guidelines, group says , WEDNESDAY, April ... for how medical organizations should interact with private companies ... Societies (CMSS). , "Physicians and patients count on medical ... medicine," Dr. Allen Lichter, CEO of the American Society ...
... In rats, approach minimized dangerous bleeding around spinal cord ... rats is raising new hope for a treatment that might ... often follows such trauma. , Researchers found that by immediately ... gene, they could halt the dangerous bleeding that occurs at ...
... ago that the genes BRCA1 and BRCA2 confer high ... for cancer prediction and therapy, especially for familial cases. ... rechts der Isar of the Technische Universitaet Muenchen), in ... the U.S., can identify another gene that increases susceptibility ...
... Older whites with less education least likely to be screened, ... few middle-aged and older white Americans are being screened for ... finish high school or receive other common cancer screenings, a ... white men and women, aged 50 and older, who took ...
... ... Barrel Safety Syringe , ... Mission Viejo, CA (Vocus) April 21, 2010 -- SafeShot Technologies, LLC , ... Dr. Robert W. Beart, Emeritus Professor of Surgery at Keck School of Medicine, University ...
Cached Medicine News:Health News:Patient-physician compatibility increases odds of following doctor's orders 2Health News:Patient-physician compatibility increases odds of following doctor's orders 3Health News:Voluntary Ethics Code Set for Medical Organizations 2Health News:Gene-Targeted Therapy Might Help Prevent Paralysis 2Health News:Gene-Targeted Therapy Might Help Prevent Paralysis 3Health News:Researchers identify a new breast and ovarian cancer susceptibility gene 2Health News:Few Over 50 Get Skin Cancer Screenings 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 3
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Performa cemented stem....
Porous foundation 480 series....
Porous foundation 440 series....
Medicine Products: